121 related articles for article (PubMed ID: 84093)
1. Natural polyclonality of spontaneous AKR leukemia and its consequences for so-called specific immunotherapy.
Olsson L; Ebbesen P
J Natl Cancer Inst; 1979 Mar; 62(3):623-7. PubMed ID: 84093
[TBL] [Abstract][Full Text] [Related]
2. Treatment of spontaneous leukemia in AKR mice with chemotherapy, immunotherapy, or interferon.
Bekesi JG; Roboz JP; Zimmerman E; Holland JF
Cancer Res; 1976 Feb; 36(2 pt 2):631-9. PubMed ID: 1082796
[TBL] [Abstract][Full Text] [Related]
3. Immunoadjuvant treatment of primary grafted and spontaneous AKR-leukemia. I. Treatment efficiency correlated to autoimmune reactivity.
Olsson L; Ebbesen P
J Immunol; 1979 Mar; 122(3):772-80. PubMed ID: 376705
[TBL] [Abstract][Full Text] [Related]
4. Graft versus leukemia. VI. Adoptive immunotherapy in combination with chemoradiotherapy for spontaneous leukemia-lymphoma in AKR mice.
Bortin MM; Rose WC; Truitt RL; Rimm AA; Saltzstein EC; Rodey GE
J Natl Cancer Inst; 1975 Nov; 55(5):1227-9. PubMed ID: 1546
[TBL] [Abstract][Full Text] [Related]
5. Clonal heterogeneity of anti-AKR/gross leukemia virus cytotoxic T lymphocytes. Evidence for two distinct antigen systems.
Azuma H; Phillips JD; Green WR
J Immunol; 1987 Oct; 139(7):2464-73. PubMed ID: 2821116
[TBL] [Abstract][Full Text] [Related]
6. Immunoadjuvant treatment of primary grafted and spontaneous AKR-leukemia. II. In vitro cytotoxicity of lymphoid cells against normal and malignant syngeneic cells and against normal allogeneic cells.
Olsson L; Ebbesen P
J Immunol; 1979 Mar; 122(3):781-6. PubMed ID: 376706
[No Abstract] [Full Text] [Related]
7. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene.
Hui KM; Sim T; Foo TT; Oei AA
J Immunol; 1989 Dec; 143(11):3835-43. PubMed ID: 2584720
[TBL] [Abstract][Full Text] [Related]
8. Cellular and humoral immunity to leukemia cells in BCG-induced growth control of a murine leukemia.
Olsson L; Florentin I; Kiger N; Mathé G
J Natl Cancer Inst; 1977 Oct; 59(4):1297-306. PubMed ID: 904001
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression.
Matis LA; Shu S; Groves ES; Zinn S; Chou T; Kruisbeek AM; Rosenstein M; Rosenberg SA
J Immunol; 1986 May; 136(9):3496-501. PubMed ID: 2420893
[TBL] [Abstract][Full Text] [Related]
10. The dependence of successful immunotherapy on adequate tumor burden as shown by the treatment of AKR leukemia with poly A-poly U.
Pendergrast WJ; Drake WP; Mardiney MR
J Natl Cancer Inst; 1975 Nov; 55(5):1223-5. PubMed ID: 1206751
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of spontaneous leukemia-lymphoma in AKR mice.
Bortin MM; Truitt RL; Rose WC; Rimm AA; Saltzstein EC
Adv Exp Med Biol; 1976; 73 Pt B():331-9. PubMed ID: 793340
[No Abstract] [Full Text] [Related]
12. The generation and specificity of cytotoxic T cells raised against syngeneic tumor cells bearing AKR/Gross murine leukemia virus antigens.
Green WR; Nowinski RC; Henney CS
J Exp Med; 1979 Jul; 150(1):51-66. PubMed ID: 109575
[TBL] [Abstract][Full Text] [Related]
13. Expression of antigens coded in murine leukemia viruses on thymocytes of allogeneic donor origin in AKR mice following syngeneic or allogeneic bone marrow transplantation.
Wustrow TP; Good RA
Cancer Res; 1985 Dec; 45(12 Pt 1):6428-35. PubMed ID: 2998600
[TBL] [Abstract][Full Text] [Related]
14. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo.
Truitt RL; Shih CY; Lefever AV; Tempelis LD; Andreani M; Bortin MM
J Immunol; 1983 Oct; 131(4):2050-8. PubMed ID: 6194224
[TBL] [Abstract][Full Text] [Related]
15. Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen.
Matis LA; Ruscetti SK; Longo DL; Jacobson S; Brown EJ; Zinn S; Kruisbeek AM
J Immunol; 1985 Jul; 135(1):703-13. PubMed ID: 2582053
[TBL] [Abstract][Full Text] [Related]
16. Specific immunotherapy with neuraminidase-modified leukemic cells: experimental and clinical trials.
Bekesi JG; Holland JF; Roboz JP
Med Clin North Am; 1977 Sep; 61(5):1083-100. PubMed ID: 330972
[TBL] [Abstract][Full Text] [Related]
17. G(AKSL2): a new cell surface antigen of the mouse related to the dualtropic mink cell focus-inducing class of murine leukemia virus detected by naturally occurring antibody.
Stockert E; DeLeo AB; O'Donnell PV; Obata Y; Old LJ
J Exp Med; 1979 Jan; 149(1):200-15. PubMed ID: 216764
[TBL] [Abstract][Full Text] [Related]
18. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
Eberlein TJ; Rosenstein M; Spiess PJ; Rosenberg SA
J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314
[TBL] [Abstract][Full Text] [Related]
19. The specificity of H-2-restricted cytotoxic T lymphocytes directed to AKR/Gross leukemia virus-induced tumors. I. Isolation of a selectively resistant variant tumor subclone.
Green WR
Eur J Immunol; 1983 Nov; 13(11):863-70. PubMed ID: 6196206
[TBL] [Abstract][Full Text] [Related]
20. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
